ICAM-1-decorated extracellular vesicles loaded with miR-146a and <i>Glut1</i> drive immunomodulation and hinder tumor progression in a murine model of breast cancer
Silvia Duarte‐Sanmiguel, Ana I. Salazar‐Puerta, Ana Panic, Daniel Dodd, Carlie Francis, Diego Alzate‐Correa, Lilibeth Ortega‐Pineda, Luke R. Lemmerman, María A. Rincon‐Benavides, Kavya Dathathreya, William Lawrence, Neil Ott, Jingjing Zhang, Binbin Deng, Shipeng Wang, Sandra Paola Santander González, David W. McComb, Eduardo Reátegui, Andre F. Palmer, William E. Carson, Natalia Higuita‐Castro, Daniel Gallego‐Perez
Abstract
) hampered tumor progression compared to ICAM-1-decorated EVs with no cargo. Flow cytometry analyses of the tumors indicated a shift in the phenotype of the immune cell population toward a more pro-inflammatory state, which appeared to have facilitated the infiltration of tumor-targeting T cells, and was associated with a reduction in tumor size and decreased metastatic burden. Altogether, our results indicate that ICAM-1-decorated EVs could be a powerful platform nanotechnology for the deployment of immune cell-targeting therapies to solid tumors.